Evidence map›Paper›PMID 38162653›Full record

ArticleFrontiers in immunology2023

IFN-γ-mediated control of SARS-CoV-2 infection through nitric oxide.

Bruno J de Andrade Silva, Paul A Krogstad, Rosane M B Teles, Priscila R Andrade, Jacob Rajfer, Monica G Ferrini, Otto O Yang, Barry R Bloom, Robert L Modlin

Abstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. MUC1 in the upper-lower airway inflammatory continuum: an endotype-centered perspective.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Review
  5. Article
  6. Review
  7. IFN-γ derived from activated human CD4Scientific reports · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Protective interplay:Frontiers in immunology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Bruno J de Andrade SilvaDivision of Dermatology, Department of Medicine, David Geffen School of Medicine at University of California (UCLA), Los Angeles, CA, United States.
Paul A KrogstadDepartment of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States.
Rosane M B TelesDivision of Dermatology, Department of Medicine, David Geffen School of Medicine at University of California (UCLA), Los Angeles, CA, United States.
Priscila R AndradeDivision of Dermatology, Department of Medicine, David Geffen School of Medicine at University of California (UCLA), Los Angeles, CA, United States.
Jacob RajferDepartment of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States.
Monica G FerriniDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States.
Otto O YangDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States.
Barry R BloomDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, United States.
Robert L ModlinDivision of Dermatology, Department of Medicine, David Geffen School of Medicine at University of California (UCLA), Los Angeles, CA, United States.

Funding

Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTON, PETER A · 1991 to 2018
$39.9M
Molecular Analysis of the Host Immune Response in LeprosyR01AI022553 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ROBERT L MODLIN · 1989 to 2026
$15.7M
TCR GAMMA/DELTA LYMPHOCYTES IN HUMAN SKIN LESIONSR01AR040312 · NIAMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MODLIN, ROBERT L · 1990 to 2025
$10.4M
Microbiology and Metagenomics CoreP50AR080594 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ROBERT L MODLIN · 2022 to 2026
$9.2M
Dynamics of the cellular and molecular architecture of human pulmonary TB granulomasR01AI166313 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ROBERT L MODLIN · 2022 to 2026
$3.2M
The skin microbiome in acneR01AR074302 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GALLO, RICHARD L, MODLIN, ROBERT L · 2018 to 2022
$2.6M
IL-26 in host defense against infection by intracellular bacteria in skinR01AR073252 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MODLIN, ROBERT L · 2019 to 2023
$2.1M
NIAID NIH HHS P30 AI028697NIAID NIH HHS R01 AI022553NIAID NIH HHS R01 AI166313NIAMS NIH HHS P50 AR080594NIAMS NIH HHS R01 AR040312NIAMS NIH HHS R01 AR073252NIAMS NIH HHS R01 AR074302
6 · The paper itself

Abstract

Introduction: The COVID-19 pandemic has highlighted the need to identify mechanisms of antiviral host defense against SARS-CoV-2. One such mediator is interferon-g (IFN-γ), which, when administered to infected patients, is reported to result in viral clearance and resolution of pulmonary symptoms. IFN-γ treatment of a human lung epithelial cell line triggered an antiviral activity against SARS-CoV-2, yet the mechanism for this antiviral response was not identified. Methods: Given that IFN-γ has been shown to trigger antiviral activity via the generation of nitric oxide (NO), we investigated whether IFN-γ induction of antiviral activity against SARS-CoV-2 infection is dependent upon the generation of NO in human pulmonary epithelial cells. We treated the simian epithelial cell line Vero E6 and human pulmonary epithelial cell lines, including A549-ACE2, and Calu-3, with IFN-γ and observed the resulting induction of NO and its effects on SARS-CoV-2 replication. Pharmacological inhibition of inducible nitric oxide synthase (iNOS) was employed to assess the dependency on NO production. Additionally, the study examined the effect of interleukin-1b (IL-1β) on the IFN-g-induced NO production and its antiviral efficacy. Results: Treatment of Vero E6 cells with IFN-γ resulted in a dose-responsive induction of NO and an inhibitory effect on SARS-CoV-2 replication. This antiviral activity was blocked by pharmacologic inhibition of iNOS. IFN-γ also triggered a NO-mediated antiviral activity in SARS-CoV-2 infected human lung epithelial cell lines A549-ACE2 and Calu-3. IL-1β enhanced IFN-γ induction of NO, but it had little effect on antiviral activity. Discussion: Given that IFN-g has been shown to be produced by CD8+ T cells in the early response to SARS-CoV-2, our findings in human lung epithelial cell lines, of an IFN-γ-triggered, NO-dependent, links the adaptive immune response to an innate antiviral pathway in host defense against SARS-CoV-2. These results underscore the importance of IFN-γ and NO in the antiviral response and provide insights into potential therapeutic strategies for COVID-19.

Indexed as

COVID-19Interferon-gammaNitric OxideAngiotensin-Converting Enzyme 2HumansSARS-CoV-2Virus ReplicationAngiotensin-Converting Enzyme 2Interferon-gammaNitric OxideCD8 lymphocytesCOVID-19interferonnitric oxideSARS-CoV-2T cell responseviral immunity

Identifiers

PMID38162653
PMCPMC10755032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.